Table 1 Clinical data and mutation status of CTNNB1 in correlation with the expression pattern of FGFR2 in adrenocortical carcinoma samples (n = 26)
Sample number | Sex [F/M] | Age [range in years] | Survival [months] | Ki-67 [%] | Hormonal activity | Nuclear staining | Cytoplasmatic staining | CTNNB1-mutation |
|---|---|---|---|---|---|---|---|---|
1 | F | 30–40 | + | + | No mutation | |||
2 | F | 40–50 | > 132 | Cortisol | 0 | + | No PCR-amplicon | |
3 | F | 20–30 | > 9 | 0 | + | No mutation | ||
4 | M | 40–50 | + | + | p.S45P | |||
5 | M | 80–90 | 0 | + | No mutation | |||
6 | F | 40–50 | 0 | + | No mutation | |||
7 | M | 60–70 | 0 | + | No mutation | |||
8 | M | 50–60 | > 48 | 30–40 | Cortisol, androgen | + | + | No mutation |
9 | M | 30–40 | 48 | Cortisol, androgen | + | + | No mutation | |
10 | F | 40–50 | > 360 | + | + | No mutation | ||
11 | M | 20–30 | > 30 | + | + | No mutation | ||
12 | F | 30–40 | > 22 | Androgen | + | + | p.S33P | |
13 | F | 40–50 | + | + | No mutation | |||
14 | M | 60–70 | + | + | No mutation | |||
15 | M | 40–50 | + | + | p.T41A | |||
16 | F | 50–60 | 99 | + | + | p.A5V | ||
17 | F | 30–40 | > 151 | 60 | + | + | No mutationa | |
18 | M | 60–70 | 0 | + | No mutation | |||
19 | F | 60–70 | 25 | + | + | No mutation | ||
20 | F | 40–50 | > 89 | 5–10 | Cortisol, androgen | 0 | + | No mutation |
21 | M | 50–60 | > 4 | Cortisol | + | + | No mutation | |
22 | F | 70–80 | > 4 | Cortisol | 0 | + | p.T41A | |
23 | F | 50–60 | 5 | Cortisol | 0 | 0 | p.L513F | |
24 | F | 50–60 | > 6 | 25 | Cortisol, androgen | 0 | 0 | |
25 | M | 50–60 | 30–40 | 0 | + | No mutation | ||
26 | M | 70–80 | + | + |